As PRP (Platelet Rich Plasma) therapy expands from orthopedics and rehabilitation into aesthetics, hair loss, infertility, ophthalmology, and anti-aging, global leader Goodmorning bio has officially announced its plan to enter the Korean domestic market. The company, a leading Medical Device Manufacturer, has long focused on exports but stated that rising interest among Korean clinicians and consumers motivated a strategic shift.

PRP is a treatment in which a patient’s own blood is processed to extract highly concentrated platelets. These platelets contain growth factors that accelerate tissue regeneration while minimizing side effects, making PRP a trusted non-surgical solution.

Research shows that growth factor concentrations within PRP can be 3–5 times higher than in normal plasma, which directly contributes to improved healing outcomes.

According to Grand View Research, the global PRP market was valued at USD 546.6 million and is projected to grow at a CAGR of over 15% through 2030. The rise of sports injuries, growing demand for aesthetic procedures, and increased PRP-related clinical research are fueling this growth.

Within this rapidly expanding environment, Goodmorning bio aims to strengthen its presence using its flagship products: PRP KIT, PRO PRP, and PRO BMC KIT, all of which have earned strong international credibility. 

The company emphasized that its PRO PRP lineup supports multiple volumes, from 10cc to 60cc, accommodating hospitals of various sizes while maintaining compatibility with standard centrifuges. The patented curved neck design minimizes cell loss, enabling physicians to extract maximum PRP volume with consistent quality.

In the United States, Goodmorning bio has supplied PRP KIT, PRO PRP, and PRO BMC KIT through OEM partnerships with APEX Biologix, which markets the products under the XCELL PRP and XCELL BMC KIT brands. This long-standing collaboration demonstrates the company’s reliability as a global Medical Device Manufacturer and highlights the strength of its product portfolio.

Goodmorning bio also developed a patented physical Activator device that enhances PRP without the use of calcium, thrombin, or other chemical agents. This eliminates the possibility of side effects while maximizing cytokine and growth factor release, reinforcing the company’s scientific leadership in regenerative medicine.

However, recent regulatory changes in Korea have presented challenges. The government’s selective reimbursement policy for PRP treatment and the announcement of PRP KIT non-reimbursement may increase financial burdens for hospitals and manufacturers. Goodmorning bio expressed concerns that clinically proven PRP treatments could become less accessible despite their safety and therapeutic value.
Goodmorning bio is a global Medical Device Manufacturer specializing in PRP and regenerative medicine technologies.

Over the past 13 years, the company has developed and produced industry-leading products such as PRP KIT, PRO PRP, and PRO BMC KIT, securing more than 20 patents and exporting to over 30 countries. With FDA certification and a strong track record of global partnerships, Goodmorning bio continues to strengthen its position as an innovative biotechnology company.

Through its entry into the Korean market, the company aims to provide high-quality products at reasonable prices while contributing to the advancement of medical treatment standards.